AKAkira Kakizuka

Akira Kakizuka

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Akira Kakizuka has a total of 13 co-authors. Here are the top co-authors by number of shared publications:

  • Masakatsu Noguchi

    Laboratory of Functional Biology, Kyoto University Graduate School of Biostudies, Kyoto 606‐8501, Japan

    2 shared publications
  • Atsushi Manno

    Laboratory of Functional Biology, Kyoto University Graduate School of Biostudies, Kyoto 606-8501, Japan

    1 shared publication
  • Chiho Mori‐Konya

    The Laboratory of Functional Biology, Kyoto University Graduate School of Biostudies and Solution Oriented Research for Science and Technology (JST), Kyoto 606-8501, Japan

    1 shared publication
  • Hiroshi Ohizumi

    The Laboratory of Functional Biology, Kyoto University Graduate School of Biostudies and Solution Oriented Research for Science and Technology (JST), Kyoto 606‐8501, Japan

    1 shared publication
  • Junpei Fukushi

    Laboratory of Functional Biology, Kyoto University Graduate School of Biostudies, Kyoto 606‐8501, Japan

    1 shared publication
  • Kunihiko Yasuda

    The Laboratory of Functional Biology, Kyoto University Graduate School of Biostudies and Solution Oriented Research for Science and Technology (JST), Kyoto 606‐8501, Japan

    1 shared publication

Latest Publications

  • Open Access

    Enhanced ATPase activities as a primary defect of mutant valosin‐containing proteins that cause inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia

    by Atsushi Manno, Masakatsu Noguchi, Junpei Fukushi, Yasuhiro Motohashi, Akira Kakizuka

    Valosin‐containing protein (VCP) has been shown to colocalize with abnormal protein aggregates, such as nuclear inclusions of Huntington disease and Machado‐Joseph disease, Lewy bodies in Parkinson disease. Several mis‐sense mutations in the human VCP gene have been identified in patients suffering inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia (IBMPFD). Recently, we have shown that VCP possesses both aggregate‐forming and aggregate‐clearing activities. Here, we showed that in cells treated with proteasome inhibitors VCP first appeared as several small aggregates throughout the cells; and then, these small aggregates gathered together into a single big aggregate. Subcellular localization and ATPase activity of VCP clearly influenced the localization of the aggregates. Furthermore, all tested IBMPFD‐causing mutant VCPs, possessed elevated ATPase activities and enhanced aggregate‐forming activities in cultured cells. In Drosophila, these mutants and VCP(T761E), a super active VCP, did not appear to spontaneously induce eye degeneration, but worsened the phenotype when co‐expressed with polyglutamines. Unexpectedly, these VCPs did not apparently change sizes and the amounts of polyglutamine aggregates in Drosophila eyes. Elevated ATPase activities, thus, may be a hidden primary defect causing IBMPFD pathological phenotypes, which would be revealed when abnormal proteins are accumulated, as typically observed in aging.


  • p97/valosin‐containing protein (VCP) is highly modulated by phosphorylation and acetylation

    by Chiho Mori‐Konya, Naruyoshi Kato, Ryota Maeda, Kunihiko Yasuda, Naoki Higashimae, Masakatsu Noguchi, Masaaki Koike, Yoko Kimura, Hiroshi Ohizumi, Seiji Hori, et al.

    P97/valosin‐containing protein (VCP) is a member of the AAA family proteins, which plays various important roles in cells by using its ATPase activity. But mechanism of regulating its ATPase activity is mostly unknown. We report here that VCP is highly modified throughout the protein via acetylation and phosphorylation. In addition to six previously identified phosphorylation sites, we identified at least 14 serines, 14 threonines, 6 tyrosines and 22 lysines as potential modification sites. Interestingly, these sites included Lys251 and Lys524, which are very critical for the ATP binding in Walker A motif of D1 and D2 domains, respectively. It is notable that 16 sites are in the N‐terminal region and 16 sites are clustered in D2α domain (from Pro646 to Gly765). Indeed, amino acid substitution of Lys696 and Thr761 profoundly affect VCP ATPase activities. From these results, we propose that D2α domain acts as a VCP ATPase Regulatory domain or “VAR domain”. VCP modifications including those in this VAR domain may endorse adaptive and multiple functions to VCP in different cell conditions such as in the cell cycle and with abnormal protein accumulation.